To help facilitate a comparison with the previously reported ECOG 3805: ChemoHormonal
Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) study, which stratified patients by high or low tumour volume, the investigators of the GETUG-AFU 15 study retrospectively assessed tumour volume and performed sub-analyses on these separate populations.
Phase III study of combined chemohormonal
therapy in metastatic prostate cancer (ECOG 3282): an Eastern Cooperative Oncology Group study.
The analysis further revealed several pathways that exhibit higher expression in hormone receptor-positive disease - some of which were also associated with a higher risk of recurrence after chemohormonal
therapy - suggesting that they may be potential therapeutic targets and providing a rationale for evaluating both currently available and investigational agents that target these pathways.
Systemic adjuvant chemohormonal
therapies reduce ipsilateral breast tumour recurrence by approximately one-third [3-5] and hormonal therapies such as tamoxifen and aromatase inhibitors can decrease the risk of contralateral disease by more than 50% [6,7].
Clinical studies have demonstrated that the combination of alternating weekly chemohormonal
therapies with Sr-89 demonstrated a prolonged progression-free and overall survival with acceptable toxicity.
Legacy treatment can consist of surgery alone, surgery plus antihormonal therapy, or surgery plus chemohormonal
therapy, depending on the stage and hormone receptor status of the tumor.
The study assessed 465 patients from a previous Eastern Cooperative Oncology Group (ECOG) study with hormone receptor-positive breast cancer, who had zero to three positive or negative axillary lymph nodes and received contemporary chemohormonal
Online  in hormone receptor-positive operable breast cancer and 0-3 positive axillary lymph nodes treated with adjuvant chemohormonal
therapy in a presentation by Lori Goldstein on behalf of the Eastern Cooperative Oncology Group (ECOG) and North American Cancer Intergroup (TBCI) (Abstr.
Researchers analyzed tumor samples from patients in the SWOG/Breast Cancer Intergroup of North America trial that evaluated postmenopausal patients with node positive, hormone receptor-positive breast cancer who were treated with chemohormonal
therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, followed by tamoxifen) vs.
in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal
therapy (CHT): an analysis of intergroup trial E2197.
For this study, researchers analyzed tumor samples from patients in the SWOG/ Breast Cancer Intergroup of North America trial that evaluated postmenopausal patients with node-positive, hormone receptor positive breast cancer who were treated with chemohormonal
therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, followed by tamoxifen) versus tamoxifen alone.
Patients with low Recurrence Score results seem to have excellent outcomes with standard chemohormonal
therapy at 5 years, even when there are positive lymph nodes.